Type of Mesothelioma:
Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications
Frontiers in Medicine 2022 April 13 [Link] Marcelo Luiz Balancin, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Cecília Farhat, Aline Kawassaki Assato, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Alexandre Muxfeldt Ab’Saber, Teresa Yae Takagaki, Vera Luiza Capelozzi Abstract Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM…
Read MoreDownregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G 1 cell cycle arrest
Oncology Letters 2022 June [Link] Takahiro Kambara, Vishwa Jeet Amatya, Kei Kushitani, Yutaro Fujii, Ihiro Endo, Yukio Takeshima Abstract Pleural malignant mesothelioma is a malignant tumor with a poor prognosis that is strongly associated with asbestos exposure during its development. Because there is no adequate treatment for malignant mesothelioma, investigation of its molecular mechanism is…
Read MoreUltra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma
Biomaterials 2022 April 20 [Link] Robert C Sabatelle, Rong Liu, Yin P Hung, Eric Bressler, Eliza J Neal, Andrew Martin, Iriny Ekladious, Mark W Grinstaff, Yolonda L Colson Abstract Peritoneal mesothelioma is an aggressive disease with a median survival of under three years, due to a lack of effective treatment options. Mesothelioma is traditionally considered…
Read MoreExpression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study
The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…
Read MoreBAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study
Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…
Read MoreNPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine
World Journal of Surgical Oncology 2022 April 30 [Link] He-Liang Wu, Zhi-Ran Yang, Li-Jun Yan, Yan-Dong Su, Ru Ma, Yan Li Abstract Background: This review systematically summarizes gene biology features and protein structure of nucleoplasmin2 (NPM2) and the relationship between NPM2 and malignant peritoneal mesothelioma (MPM), in order to explore the molecular pathological mechanism of…
Read MoreA Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
Journal of Thoracic Oncology 2022 May [Link] Jennifer G Whisenant, Javier Baena, Alessio Cortellini, Li-Ching Huang, Giuseppe Lo Russo, Luca Porcu, Selina K Wong, Christine M Bestvina, Matthew D Hellmann, Elisa Roca, Hira Rizvi, Isabelle Monnet, Amel Boudjemaa, Jacobo Rogado, Giulia Pasello, Natasha B Leighl, Oscar Arrieta, Avinash Aujayeb, Ullas Batra, Ahmed Y Azzam, Mojca…
Read MoreMedical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations
Journal of Thoracic Oncology 2022 April 21 [Link] Michele Carbone, Harvey I Pass, Guntulu Ak, H Richard Alexander Jr, Paul Baas, Francine Baumann, Andrew M Blakely, Raphael Bueno, Aleksandra Bzura, Giuseppe Cardillo, Jane E Churpek, Irma Dianzani, Assunta De Rienzo, Mitsuru Emi, Salih Emri, Emanuela Felley-Bosco, Dean A Fennell, Raja M Flores, Federica Grosso, Nicholas…
Read MoreMicro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…
Read MoreFeasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…
Read More